2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
Date Title
Dec 03, 2018Printer Friendly VersionSeattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Dec 02, 2018Printer Friendly VersionTakeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Nov 27, 2018Printer Friendly VersionEuropean Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe
Nov 01, 2018Printer Friendly VersionTakeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers
Oct 25, 2018Printer Friendly VersionTakeda to Highlight Data in Hodgkin Lymphoma During the 11th International Symposium on Hodgkin Lymphoma
Oct 19, 2018Printer Friendly VersionTakeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
Oct 01, 2018Printer Friendly VersionSeattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Sep 25, 2018Printer Friendly VersionTakeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC
Sep 21, 2018Printer Friendly VersionTakeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
Jul 25, 2018Printer Friendly VersionTakeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve
Jul 11, 2018Printer Friendly VersionPhase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant
May 17, 2018Printer Friendly VersionTakeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
Mar 22, 2018Printer Friendly VersionTakeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood
Mar 01, 2018Printer Friendly VersionMultiple Myeloma Patients, Caregivers and Health Care Professionals Trekking to the Doorstep of the World’s Tallest Mountain, Mt. Everest
Jan 22, 2018Printer Friendly VersionEuropean Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients